Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business JournalGlobeNewsWire • 05/09/22
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple MyelomaGlobeNewsWire • 04/27/22
Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ ProductsGlobeNewsWire • 04/14/22
Allogene Therapeutics Announces Participation in Seven Upcoming Investor ConferencesGlobeNewsWire • 04/12/22
Why Is Allogene Therapeutics (ALLO) Up 7.4% Since Last Earnings Report?Zacks Investment Research • 03/25/22
Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple MyelomaGlobeNewsWire • 03/23/22
Allogene Therapeutics (ALLO) Soars 8.4%: Is Further Upside Left in the Stock?Zacks Investment Research • 03/21/22
Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell CarcinomaGlobeNewsWire • 03/10/22
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/24/22
Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 02/23/22
Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022GlobeNewsWire • 02/16/22
Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor ConferencesGlobeNewsWire • 01/26/22
Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ TechnologyGlobeNewsWire • 01/11/22